Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by Stanley Muller on Aug 25th, 2026

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $42.00.

CSTL has been the topic of a number of research analyst reports. Robert W. Baird set a $36.00 price target on Castle Biosciences in a research report on Friday, July 31st. KeyCorp set a $35.00 price objective on shares of Castle Biosciences in a research note on Friday, May 29th. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, BTIG Research lifted their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd.

Check Out Our Latest Report on CSTL

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Tobin W. Juvenal sold 17,310 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $29.31, for a total transaction of $507,356.10. Following the transaction, the insider owned 80,725 shares in the company, valued at $2,366,049.75. This trade represents a 17.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,587 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $20.71, for a total transaction of $177,836.77. Following the transaction, the chief operating officer directly owned 30,460 shares in the company, valued at approximately $630,826.60. This represents a 21.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 136,305 shares of company stock valued at $3,841,714 in the last ninety days. 6.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Advisors Capital Management LLC bought a new position in Castle Biosciences in the 2nd quarter valued at approximately $5,681,000. Summit Partners Public Asset Management LLC grew its position in shares of Castle Biosciences by 164.7% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after buying an additional 658,725 shares during the last quarter. SummitTX Capital L.P. increased its position in Castle Biosciences by 285.0% during the 1st quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock valued at $1,646,000 after purchasing an additional 49,623 shares during the period. Quantinno Capital Management LP increased its position in shares of Castle Biosciences by 387.3% during the first quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock worth $1,116,000 after buying an additional 36,144 shares during the period. Finally, AIGH Capital Management LLC acquired a new stake in Castle Biosciences during the 2nd quarter worth about $13,001,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Trading Down 2.1%

NASDAQ CSTL opened at $33.47 on Thursday. The company has a market capitalization of $1.02 billion, a PE ratio of -50.71 and a beta of 0.98. The stock has a 50-day simple moving average of $26.16 and a 200 day simple moving average of $25.39. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. Castle Biosciences has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.34. The business had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. Research analysts forecast that Castle Biosciences will post -1.29 EPS for the current year.

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.